CoChat

Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise

Open access
Brines, M., Cerami, A. · 2006 · Kidney International

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

A greatly expanded understanding of the biology of endogenous erythropoietin (EPO) has emerged since the early 1990s. Originally viewed as the renal hormone dedicated to erythrocyte production, it is now clear that EPO is produced locally by many other tissues in response to physical or metabolic stress. In its autocrine-paracrine roles, EPO mediates preconditioning (ischemic tolerance) and specifically limits the destructive potential of tumor necrosis factor alpha and other proinflammatory cytokines in the brain, heart, kidney, and other tissues. As local production of EPO is generally suppressed following injury, administration of exogenous EPO has been a successful therapeutic approach in preclinical and clinical studies, for example, following ischemia-reperfusion and toxin-induced renal injuries, and in human stroke. The therapeutic time window of tissue protection by EPO is typically very wide in experimental models, showing effectiveness when administered before, during, or after an insult and raising optimism for a high clinical potential. Although there is progress in understanding the signaling pathways responsible for EPO's tissue-protective actions that are similar to, but not as redundant as, those employed for erythrocyte maturation, much work remains to be carried out. Experimental observations also suggest the existence of EPO receptor (EPOR) isoforms mediating EPO's diverse biological activities and have identified a tissue-protective receptor complex consisting of the EPOR and the beta common receptor (CD131) subunit that is also employed by granulocyte-macrophage colony-stimulating factor, interleukin-3 and interleukin-5. Successfully engineered analogues of EPO that selectively activate tissue protection without stimulating hematopoiesis confirm the concept of a tissue-protective receptor and have significant potential utility in the investigational and therapeutic arenas.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.ki.5001546

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

See all 293

Metadata

Authors
Brines, M., & Cerami, A.
Corresponding author
Brines, M.
Venue
Kidney International
Publisher
Elsevier BV
Published
2006-07
Volume
70
Issue
2
Pages
246-250
ISSN
0085-2538 (ISSN-L)
OpenAlex
W2160549233
Cited by
290
References
27
Citations by year
2026: 6 · 2025: 1 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 9 · 2020: 8 · 2019: 7 · 2018: 10 · 2017: 16 · 2016: 16 · 2015: 9 · 2014: 10 · 2013: 23 · 2012: 19
FWCI
18.83
Type
journal article
Language
en
Open access
Licence
Locations
  • Kidney International (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heme Oxygenase-1 and Carbon Monoxide
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Keywords
erythropoietin, ischemic preconditioning, ischemic tolerance, tissue protection, TNF-α, inflammatory cytokines, kidney injury, ischemia-reperfusion injury, stroke, CD131, autocrine and paracrine signaling
MeSH terms
Animals, Endothelium, Vascular, Erythropoietin, Humans, Kidney, Kidney Diseases, Reperfusion Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise. https://app.cochat.ai/papers/10.1038/sj.ki.5001546
The paper
Brines, M., & Cerami, A. (2006). Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise. Kidney International. https://doi.org/10.1038/sj.ki.5001546

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.